

Amendments to the Claims:

Claims 1-19 (Canceled)

20. (Previously presented) A method of treating non-Hodgkin's B-cell lymphoma in a human subject, said method comprising administering to said subject at least one therapeutically effective dose of an anti-CD20 antibody or fragment thereof in combination with administration of at least one therapeutically effective dose of interleukin-2 (IL-2) or variant thereof, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 125 mg/m² to about 500 mg/m² and said therapeutically effective dose of said IL-2 or variant thereof is in the range from about 1 mIU/m² to about 14 mIU/m².

21. (Previously presented) The method of claim 20, wherein said therapeutically effective dose of said IL-2 or variant thereof is in the range from about 2 mIU/m² to about 12 mIU/m².

22. (Previously presented) The method of claim 21, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m² to about 400 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is in the range from about 3 mIU/m² to about 6 mIU/m².

23. (Previously presented) The method of claim 22, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is about 375 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 4.5 mIU/m².

24. (Previously presented) The method of claim 22, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225

mg/m² to about 400 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 6 mIU/m².

25. (Previously presented) The method of claim 20, wherein said IL-2 or variant thereof is administered subcutaneously.

26. (Previously presented) The method of claim 20, wherein said IL-2 or variant thereof is administered as a pharmaceutical composition selected from the group consisting of a monomeric IL-2 pharmaceutical composition, a multimeric IL-2 composition, a lyophilized IL-2 pharmaceutical composition, and a spray-dried IL-2 pharmaceutical composition.

27. (Previously presented) The method of claim 20, wherein said IL-2 is recombinantly produced IL-2 having an amino acid sequence for human IL-2, and said variant thereof has an amino acid sequence having at least about 70% sequence identity to the amino acid sequence for human IL-2.

28. (Previously presented) The method of claim 27, wherein said variant is des-alanyl-1, serine-125 human IL-2.

29. (Previously presented) The method of claim 20, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody.

30. (Previously presented) The method of claim 29, wherein said chimeric anti-CD20 antibody is IDEC-C2B8.

31. (Currently amended) The method of claim 20, wherein said ~~concurrent therapy~~ method comprises a first administration of said therapeutically effective dose of said anti-CD20 antibody or fragment thereof to said subject on day 1 of a treatment period followed by a first administration of said therapeutically effective dose of said IL-2 or variant thereof to said subject

within 7 days of said first administration of said therapeutically effective dose of said anti-CD20 antibody or fragment thereof.

32. (Previously presented) The method of claim 31, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is administered once a week for a period of 4 weeks, and said therapeutically effective dose of said IL-2 or variant thereof is administered daily beginning on day 8 of said treatment period.

33. (Currently amended) The method of claim 32, wherein said therapeutically effective dose of said IL-2 or variant thereof is administered daily for a period of 4 weeks beginning on day 8 of said treatment period.

34. (Previously presented) The method of claim 33, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m² to about 400 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is in the range from about 3 mIU/m² to about 6 mIU/m².

35. (Previously presented) The method of claim 34, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is about 375 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 4.5 mIU/m².

36. (Previously presented) The method of claim 31, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is administered once a week for a period of 4 weeks, and said therapeutically effective dose of said IL-2 or variant thereof is administered three times per week beginning on day 8 of said treatment period.

37. (Currently amended) The method of claim 36, wherein said therapeutically effective dose of said IL-2 or variant thereof is administered three times a week for a period of 4 weeks beginning on day 8 of said treatment period.

38. (Previously presented) The method of claim 37, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m² to about 400 mg/m² and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 6 mIU/m².

39. (Previously presented) The method of claim 31, wherein said IL-2 or variant thereof is administered subcutaneously.

40. (Previously presented) The method of claim 31, wherein said IL-2 or variant thereof is administered as a pharmaceutical composition selected from the group consisting of a monomeric IL-2 pharmaceutical composition, a multimeric IL-2 composition, a lyophilized IL-2 pharmaceutical composition, and a spray-dried IL-2 pharmaceutical composition.

41. (Previously presented) The method of claim 31, wherein said IL-2 is recombinantly produced IL-2 having an amino acid sequence for human IL-2, and said variant thereof has an amino acid sequence having at least about 70% sequence identity to the amino acid sequence for human IL-2.

42. (Previously presented) The method of claim 41, wherein said variant is des-alanyl-1, serine-125 human IL-2.

43. (Previously presented) The method of claim 31, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody or fragment thereof.

44. (Previously presented) The method of claim 43, wherein said chimeric anti-CD20 antibody is IDEC-C2B8 or fragment thereof.